Acamprosate in the treatment of binge eating disorder: A placebo-controlled trial

2010 ◽  
Vol 44 (1) ◽  
pp. 81-90 ◽  
Author(s):  
Susan L. McElroy ◽  
Anna I. Guerdjikova ◽  
Erin L. Winstanley ◽  
Anne M. O'Melia ◽  
Nicole Mori ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Controlled Trial

Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial

2016 ◽  
Vol 31 (5) ◽  
pp. 382-391 ◽  
Author(s):  
Anna I. Guerdjikova ◽  
Nicole Mori ◽  
Thomas J. Blom ◽  
Paul E. Keck ◽  
Stephanie L. Williams ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Controlled Trial ◽  
Lisdexamfetamine Dimesylate

Adapted motivational interviewing for women with binge eating disorder: A randomized controlled trial.

2008 ◽  
Vol 22 (3) ◽  
pp. 417-425 ◽  
Author(s):  
Stephanie E. Cassin ◽  
Kristin M. von Ranson ◽  
Kenneth Heng ◽  
Joti Brar ◽  
Amy E. Wojtowicz
Keyword(s):  
Randomized Controlled Trial ◽  
Eating Disorder ◽  
Binge Eating ◽  
Motivational Interviewing ◽  
Binge Eating Disorder ◽  
Controlled Trial ◽  
Randomized Controlled

scholarly journals Predictive significance of the overvaluation of shape/weight in obese patients with binge eating disorder: findings from a randomized controlled trial with 12-month follow-up

2012 ◽  
Vol 43 (6) ◽  
pp. 1335-1344 ◽  
Author(s):  
C. M. Grilo ◽  
M. A. White ◽  
R. Gueorguieva ◽  
G. T. Wilson ◽  
R. M. Masheb
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Controlled Trial ◽  
Prognostic Significance ◽  
Self Esteem ◽  
Obese Patients ◽  
Undue Influence ◽  
Co Morbidity

BackgroundUndue influence of body shape or weight on self-evaluation – referred to as overvaluation – is considered a core feature across eating disorders, but is not a diagnostic requirement for binge eating disorder (BED). This study examined the concurrent and predictive significance of overvaluation of shape/weight in obese patients with BED participating in a randomized clinical trial testing cognitive behavioral therapy (CBT) and behavioral weight loss (BWL).MethodA total of 90 participants were randomly assigned to 6-month group treatments of CBT or BWL. Assessments were performed at baseline, throughout- and post-treatment, and at 6- and 12-month follow-ups after completing treatments with reliably administered semi-structured interviews and established measures.ResultsParticipants categorized with overvaluation (n = 52, 58%) versus without overvaluation (n = 38, 42%) did not differ significantly in demographic features (age, gender and ethnicity), psychiatric co-morbidity, body mass index or binge eating frequency. The overvaluation group had significantly greater levels of eating disorder psychopathology and poorer psychological functioning (higher depression and lower self-esteem) than the non-overvaluation group. Overvaluation of shape/weight significantly predicted non-remission from binge eating and higher frequency of binge eating at the 12-month follow-up, even after adjusting for group differences in depression and self-esteem levels.ConclusionsOur findings suggest that overvaluation does not simply reflect concern commensurate with being obese or more frequent binge eating, but also is strongly associated with heightened eating-related psychopathology and psychological distress, and has negative prognostic significance for longer-term treatment outcomes. Overvaluation of shape/weight warrants consideration as a diagnostic specifier for BED as it provides important information about severity and treatment outcome.

Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder

2021 ◽  
Vol 110 ◽  
pp. 106587
Author(s):  
Anna I. Guerdjikova ◽  
Francisco Romo-Nava ◽  
Thomas J. Blom ◽  
Nicole Mori ◽  
Susan L. McElroy
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Study Protocol ◽  
Binge Eating Disorder ◽  
Controlled Trial
Sign in / Sign up

Export Citation Format

Share Document